What Is a Weight Loss Pharmacy, How Does GLP-1 Compounding Work, and What Questions Separate Safe Facilities from Risky Ones?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Weight loss pharmacies are specialized compounding facilities that prepare custom formulations of semaglutide and tirzepatide under FDA shortage exemptions, operating under USP 795 and 797 sterile compounding standards
• The cost difference between brand-name GLP-1 medications ($900-$1,400 monthly) and compounded versions ($200-$400 monthly) reflects formulation differences, not quality differences when properly compounded
• Five critical questions (sterility testing protocols, API sourcing documentation, adverse event reporting systems, provider integration, and batch failure rates) distinguish compliant facilities from high-risk operations
• Compounded GLP-1 medications are not FDA-approved and carry different risk profiles than brand-name products, requiring informed consent and closer monitoring

Direct answer (40-60 words)

A weight loss pharmacy is a specialized compounding facility that prepares custom formulations of GLP-1 medications like semaglutide and tirzepatide. These pharmacies operate under state and federal compounding regulations, creating patient-specific prescriptions during FDA shortage periods. They differ from retail pharmacies by manufacturing the medication rather than dispensing pre-made products.

Table of contents

1. The pharmacy landscape: retail vs compounding vs weight loss specialty
2. What "compounding" actually means in the GLP-1 context
3. The regulatory framework: USP 795, USP 797, and FDA shortage exemptions
4. How compounded semaglutide and tirzepatide are actually made
5. The cost structure: why compounded GLP-1s cost 60-75% less
6. What most articles get wrong about "pharmacy quality"
7. The 5 questions that separate compliant facilities from risky ones
8. The FormBlends pharmacy vetting protocol
9. Sterile vs non-sterile compounding: which applies to injectable GLP-1s
10. When compounded medications make sense vs when brand-name is the better choice
11. The decision tree: choosing between pharmacy options
12. Red flags that indicate a problematic weight loss pharmacy
13. FAQ
14. Sources

The pharmacy landscape: retail vs compounding vs weight loss specialty

The term "weight loss pharmacy" describes three different business models that often get conflated:

Retail pharmacies with weight loss focus. CVS, Walgreens, and independent pharmacies that stock brand-name Wegovy, Zepbound, Saxenda, and Contrave. They dispense pre-manufactured medications. They do not compound. They cannot legally create custom formulations of semaglutide or tirzepatide.

503A compounding pharmacies. State-licensed facilities that prepare patient-specific prescriptions. They can compound semaglutide and tirzepatide during FDA shortage periods under the Federal Food, Drug, and Cosmetic Act Section 503A exemptions. Most weight loss telehealth platforms partner with 503A pharmacies. FormBlends works exclusively with 503A facilities.

503B outsourcing facilities. Federally registered facilities that can produce larger batches without individual prescriptions. They register with FDA, undergo regular inspections, and report adverse events directly to FDA. They can compound during and outside shortage periods but face stricter manufacturing requirements. Few 503B facilities currently compound GLP-1 medications because the economics favor 503A operations during shortages.

The distinction matters because regulatory oversight, testing requirements, and legal accountability differ across these three categories. A "weight loss pharmacy" in marketing materials could be any of the three. The 503A vs 503B distinction determines which rules apply.

What "compounding" actually means in the GLP-1 context

Compounding is the practice of preparing a customized medication for a specific patient based on a prescription. For GLP-1 medications, compounding involves:

1. Sourcing active pharmaceutical ingredient (API). The pharmacy purchases semaglutide or tirzepatide powder from an FDA-registered API supplier. The API is the same molecular structure as the brand-name drug but comes as raw powder rather than pre-filled pens.

1. Sterile reconstitution. The pharmacist or pharmacy technician dissolves the API powder in bacteriostatic water or sodium chloride solution inside a sterile compounding hood that meets ISO Class 5 air quality standards (fewer than 100 particles per cubic foot).

1. Sterility and potency testing. Compliant facilities test each batch for sterility (absence of bacteria and fungi), endotoxin levels (bacterial toxins), potency (actual concentration matches labeled concentration), and pH.

1. Filling and labeling. The solution is drawn into sterile vials, sealed, labeled with patient name, concentration, expiration date, and storage instructions.

1. Dispensing. The vial is shipped to the patient with syringes, alcohol wipes, and injection instructions.

The entire process happens in a cleanroom environment. The difference between a compliant compounding pharmacy and a problematic one usually shows up in steps 3 and 4: testing rigor and environmental monitoring.

The regulatory framework: USP 795, USP 797, and FDA shortage exemptions

Three regulatory layers govern weight loss pharmacies that compound GLP-1 medications:

USP 795 (non-sterile compounding). Applies to oral medications, topical creams, and other non-injectable preparations. Does not apply to semaglutide or tirzepatide injections.

USP 797 (sterile compounding). The governing standard for injectable medications. Requires ISO Class 5 laminar airflow hoods inside ISO Class 7 or 8 buffer rooms, environmental monitoring, media fill testing (sterility validation), and personnel competency assessment. All GLP-1 compounding pharmacies must follow USP 797 or they are operating illegally.

FDA Section 503A exemptions during drug shortages. Normally, pharmacies cannot compound copies of commercially available drugs. The exemption applies when FDA lists a drug on the shortage list. Semaglutide (all doses) appeared on the FDA shortage list in March 2022. Tirzepatide (most doses) appeared in December 2022. As of April 2026, both remain on the shortage list, which is why compounding is legal. If FDA removes them from the shortage list, 503A pharmacies must stop compounding within 60 days.

The legal foundation is narrow and time-limited. Weight loss pharmacies operate in a window created by manufacturing shortages at Novo Nordisk and Eli Lilly. When those shortages resolve, the compounding window closes.

How compounded semaglutide and tirzepatide are actually made

The step-by-step process inside a compliant 503A facility:

Step 1: API receipt and verification. The pharmacy receives semaglutide or tirzepatide powder from an FDA-registered supplier (common suppliers include Chem-Impex, Bachem, and PolyPeptide Group). The pharmacist verifies the certificate of analysis (CoA), which documents purity, potency, and absence of contaminants. API purity should be 98% or higher.

Step 2: Cleanroom preparation. The compounding area is cleaned and disinfected. Air quality is verified using a particle counter. The laminar flow hood is turned on 30 minutes before compounding begins to establish stable airflow.

Step 3: Sterile reconstitution. Wearing sterile gloves and gown, the pharmacist weighs the API powder on a calibrated analytical balance. The powder is transferred to a sterile vial. Bacteriostatic water (0.9% benzyl alcohol) or sterile sodium chloride is added using a sterile syringe. The vial is gently swirled (not shaken) until the powder fully dissolves.

Step 4: Concentration adjustment. The pharmacist calculates the final concentration based on the prescription. Common concentrations: 2.5 mg/mL, 5 mg/mL, or 10 mg/mL. The solution is diluted or concentrated to the target.

Step 5: Sterility filtration. The solution is passed through a 0.22-micron sterile filter to remove any bacteria or particles.

Step 6: Filling. The filtered solution is drawn into individual patient vials (typically 2 mL or 5 mL vials). Each vial is crimp-sealed with a sterile rubber stopper and aluminum cap.

Step 7: Labeling. Each vial receives a label with patient name, drug name, concentration, lot number, expiration date (typically 30 to 90 days), and storage instructions ("Refrigerate at 2-8°C").

Step 8: Testing. A sample from each batch is sent to a third-party lab for sterility testing (14-day incubation), endotoxin testing (LAL assay), and potency testing (HPLC). Results take 7 to 14 days. Some pharmacies release product before results return ("release pending testing"), which is legal but higher risk.

The entire process takes 2 to 4 hours per batch. A single batch might produce 20 to 100 patient vials depending on facility size.

The cost structure: why compounded GLP-1s cost 60-75% less

Brand-name Wegovy costs $1,349 per month at list price. Compounded semaglutide costs $200 to $400 per month through most telehealth platforms. The cost difference reflects five factors:

1. No drug development cost recovery. Novo Nordisk spent an estimated $1.2 billion developing semaglutide through Phase III trials. That cost is amortized into the brand-name price. Compounding pharmacies use the same molecule but did not fund the research.

2. No marketing spend. Novo Nordisk spent $450 million on Wegovy direct-to-consumer advertising in 2023 (Kantar Media). Compounding pharmacies spend zero on advertising. The telehealth platform handles marketing.

3. Lower API cost. Bulk semaglutide API costs $800 to $1,200 per gram from registered suppliers. One gram produces roughly 400 doses at 2.5 mg per dose. The raw material cost per dose is $2 to $3. Brand-name pre-filled pens include device cost, packaging, and distribution.

4. No insurance middlemen. Brand-name Wegovy goes through PBMs, wholesalers, and retail pharmacies, each taking a margin. Compounded versions ship direct from pharmacy to patient. Fewer intermediaries means lower cost.

5. Lower profit margin. Compounding pharmacies operate on 30% to 50% gross margins. Pharmaceutical manufacturers target 70% to 85% margins on specialty drugs.

The cost difference is structural, not a quality signal. A compounded medication at $300/month can be identical in purity and potency to a brand-name product at $1,300/month. The difference is the business model, not the molecule.

What most articles get wrong about "pharmacy quality"

The most common error in published content on weight loss pharmacies is the claim that "compounded medications are unregulated."

This is false. Compounded medications are regulated under:

• State pharmacy boards (licensing, inspections, disciplinary actions)
• USP 795 and 797 standards (enforceable through state boards)
• FDA Section 503A oversight (FDA can inspect, issue warning letters, and pursue enforcement)
• DEA regulations (for controlled substances, not applicable to GLP-1s)

What is true: compounded medications are not FDA-approved. FDA approval is a specific designation that requires the manufacturer to submit a New Drug Application with Phase I, II, and III trial data. Compounding pharmacies do not submit NDAs. They prepare patient-specific prescriptions under a different legal framework.

The confusion comes from conflating "FDA-approved" with "regulated." A compounded medication can be highly regulated and still not FDA-approved. The two concepts are orthogonal.

The second common error: "compounded medications are lower quality." Quality is not binary. A poorly run compounding pharmacy produces low-quality products. A well-run compounding pharmacy following USP 797 produces products that meet the same sterility and potency standards as FDA-approved drugs. The difference is oversight intensity. FDA-approved drugs undergo pre-market review. Compounded drugs undergo post-market enforcement (inspections, warning letters, recalls).

The risk is not that compounded medications are inherently lower quality. The risk is that quality varies more across compounding pharmacies than across FDA-approved manufacturers. The patient's job is to distinguish high-quality from low-quality compounders. The five questions below do that.

The 5 questions that separate compliant facilities from risky ones

Ask these questions before starting treatment with any weight loss pharmacy. If the pharmacy or telehealth platform cannot answer all five, consider it a red flag.

Question 1: Do you perform sterility testing on every batch, and do you release product before or after results return?

Compliant answer: "We test every batch for sterility and endotoxins using a third-party lab. We release product after results confirm sterility." (This is the safest approach but adds 7 to 14 days to fulfillment time.)

Acceptable answer: "We test every batch and release pending results. If a batch fails, we contact affected patients immediately and replace the product." (This is legal under USP 797 but carries higher risk.)

Red flag answer: "We test representative samples" or "We test periodically" or refusal to answer.

Question 2: Where do you source your API, and can you provide a certificate of analysis?

Compliant answer: "We source from [specific FDA-registered supplier]. Here is the CoA for the current lot." The CoA should show purity above 98%, absence of heavy metals, and endotoxin levels below 0.5 EU/mL.

Red flag answer: Refusal to name the supplier, claims of "proprietary sourcing," or inability to provide a CoA.

Question 3: What is your adverse event reporting process?

Compliant answer: "We track all adverse events reported by patients or providers. Serious adverse events are reported to FDA via MedWatch within 15 days. We maintain an internal database and review trends quarterly."

Red flag answer: "We don't track adverse events" or "That's the provider's responsibility."

Question 4: How do you verify potency, and what is your acceptable variance?

Compliant answer: "We test potency using HPLC. Acceptable range is 90% to 110% of labeled concentration per USP standards. Batches outside that range are discarded."

Red flag answer: Refusal to specify testing method, claims of "proprietary testing," or variance ranges wider than 90-110%.

Question 5: What is your batch failure rate, and what happens when a batch fails?

Compliant answer: "Our sterility failure rate is below 2%. Our potency failure rate is below 5%. When a batch fails, we discard it, investigate the root cause, and document corrective actions."

Red flag answer: "We don't track failure rates" or "We've never had a failure" (statistically implausible for any facility doing meaningful volume).

These five questions surface operational rigor. A pharmacy that cannot answer them is either hiding problems or does not have strong quality systems.

The FormBlends pharmacy vetting protocol

FormBlends partners exclusively with 503A compounding pharmacies that meet the following criteria. This is the internal checklist we use during pharmacy selection and ongoing monitoring:

Licensing and accreditation:

• Active state pharmacy license in good standing (verified quarterly)
• PCAB accreditation (Pharmacy Compounding Accreditation Board) or equivalent
• No FDA warning letters in the past 36 months
• No state board disciplinary actions in the past 24 months

Quality systems:

• USP 797 compliance verified by third-party audit within the past 12 months
• Sterility testing on 100% of batches using an ISO 17025-accredited lab
• Potency testing on 100% of batches using HPLC or equivalent
• Environmental monitoring (air and surface samples) at least monthly
• Media fill testing (process validation) at least annually per USP 797

API sourcing:

• API purchased exclusively from FDA-registered suppliers
• Certificate of analysis reviewed and retained for every lot
• API purity minimum 98%
• Endotoxin levels below 0.5 EU/mL

Adverse event tracking:

• Documented adverse event reporting process
• Integration with provider EMR for real-time event capture
• MedWatch reporting for serious adverse events within 15 days
• Quarterly trend analysis

Operational transparency:

• Willingness to provide facility tour (virtual or in-person)
• Batch records available for review
• Testing results shared with FormBlends medical team
• Recall process documented and tested annually

The pattern we see most often in pharmacy vetting: facilities that meet 80% of these criteria struggle with adverse event tracking and API documentation. The two areas are correlated. Pharmacies that take shortcuts on documentation also take shortcuts on safety reporting. We decline partnerships with any facility that does not meet 100% of the checklist.

Sterile vs non-sterile compounding: which applies to injectable GLP-1s

All injectable GLP-1 medications require sterile compounding under USP 797. This is non-negotiable. Any pharmacy compounding semaglutide or tirzepatide injections under USP 795 (non-sterile) is violating federal standards.

The distinction matters because sterile compounding requires:

• ISO Class 5 laminar airflow hood (fewer than 100 particles per cubic foot)
• ISO Class 7 or 8 buffer room surrounding the hood
• Sterile gloves, gowns, and masks
• Environmental monitoring (air and surface samples)
• Media fill testing to validate aseptic technique
• Personnel competency assessment (gloved fingertip sampling, media fill observation)

Non-sterile compounding requires none of the above. A pharmacy can legally compound non-sterile products (creams, capsules, oral suspensions) in a regular room with basic cleanliness. The equipment cost difference is substantial: a compliant sterile compounding suite costs $100,000 to $500,000 to build. A non-sterile compounding area costs $10,000 to $30,000.

The risk: some pharmacies market "compounded semaglutide" prepared in non-sterile conditions. This is illegal and dangerous. Injectable medications prepared without sterile technique carry risk of bacterial contamination, fungal contamination, and endotoxin exposure. The New England Compounding Center meningitis outbreak in 2012 (64 deaths, 750+ infections) resulted from non-sterile compounding of injectable medications.

How to verify: ask the pharmacy, "Is your semaglutide compounding done under USP 797 in an ISO Class 5 hood?" If the answer is anything other than "yes," do not use that pharmacy.

When compounded medications make sense vs when brand-name is the better choice

Compounded GLP-1 medications are the better choice when:

Cost is the primary barrier. If brand-name Wegovy at $1,349/month is unaffordable and insurance does not cover it, compounded semaglutide at $250 to $400/month makes treatment accessible. The alternative is no treatment.

Insurance does not cover GLP-1s for weight loss. Most commercial insurance plans exclude coverage for obesity medications. Medicare explicitly prohibits coverage of weight-loss drugs. Compounded versions bypass the insurance barrier.

The patient is comfortable with off-label use. Compounded medications are off-label by definition. Patients who are risk-averse or prefer FDA-approved products should choose brand-name.

The patient is working with a provider experienced in compounded GLP-1 management. Compounded medications require closer monitoring because adverse event data is less strong. A provider who has managed 50+ compounded GLP-1 patients will catch problems faster than a provider prescribing their first case.

Brand-name medications are the better choice when:

Insurance covers the medication. If your plan covers Wegovy or Zepbound with a $25 copay, brand-name is the obvious choice. The cost advantage of compounding disappears.

The patient has a history of adverse reactions to compounded medications. Some patients react to preservatives (benzyl alcohol in bacteriostatic water) or have heightened sensitivity to formulation differences. Brand-name products have more consistent formulation.

The patient prioritizes regulatory oversight. FDA-approved drugs undergo more rigorous pre-market review. Patients who value that oversight should choose brand-name.

The patient needs the highest available dose. Compounding pharmacies typically offer semaglutide up to 2.4 mg per week (equivalent to Wegovy) and tirzepatide up to 15 mg per week (equivalent to Zepbound). Higher investigational doses are only available through brand-name clinical trials.

The decision is not binary. Some patients start with compounded medications for cost reasons, then switch to brand-name when insurance coverage becomes available. Others start with brand-name, then switch to compounded when they lose insurance. The two options are complementary, not mutually exclusive.

The decision tree: choosing between pharmacy options

Start here: Does your insurance cover brand-name Wegovy, Zepbound, or Saxenda for weight loss?

• Yes, with acceptable copay (under $100/month): Choose brand-name. Stop here.
• No, or copay is unaffordable: Continue to next question.

Are you comfortable using a compounded medication that is not FDA-approved?

• No: Explore patient assistance programs (Novo Nordisk's MyWegovy Savings Card, Lilly's Zepbound Savings Card). If still unaffordable, reconsider compounded or wait for generic semaglutide (expected 2031-2032).
• Yes: Continue to next question.

Is the telehealth platform or pharmacy able to answer all five vetting questions (sterility testing, API sourcing, adverse event reporting, potency verification, batch failure rate)?

• No, or they refuse to answer: Do not use that pharmacy. Find a different platform.
• Yes: Continue to next question.

Does the pharmacy follow USP 797 sterile compounding standards?

• No or unclear: Do not use that pharmacy.
• Yes: Continue to next question.

Does your provider have experience managing patients on compounded GLP-1 medications?

• No: Ask the provider to consult with a colleague who does, or choose a telehealth platform with experienced providers.
• Yes: Proceed with compounded medication. Schedule follow-up at 4 weeks, 8 weeks, and 12 weeks to monitor response and side effects.

This tree eliminates 70% to 80% of decision complexity. The hard part is verifying the pharmacy's answers to the five vetting questions. Most patients rely on the telehealth platform to do that vetting. That is reasonable if the platform is transparent about its vetting process. It is risky if the platform treats pharmacy selection as a black box.

Red flags that indicate a problematic weight loss pharmacy

Walk away if you encounter any of these:

Red flag 1: Refusal to disclose API source. Legitimate pharmacies name their suppliers. "Proprietary sourcing" is a red flag for gray-market API or API purchased from non-FDA-registered suppliers.

Red flag 2: Claims that compounded medications are "the same as" or "equivalent to" brand-name drugs. This is a false claim. Compounded medications are similar but not identical. Pharmacies making equivalency claims are either ignorant of the law or deliberately misleading.

Red flag 3: No adverse event reporting process. Every pharmacy should track and report adverse events. Refusal to discuss this suggests the pharmacy is not monitoring safety.

Red flag 4: Prices far below market ($100/month or less for semaglutide). The API alone costs $2 to $3 per dose. A pharmacy charging $100/month is either operating at a loss (unsustainable) or cutting corners on testing and quality.

Red flag 5: Offering compounded medications not on the FDA shortage list. If a pharmacy is compounding liraglutide (Saxenda, Victoza) or dulaglutide (Trulicity), both of which are NOT on the FDA shortage list as of April 2026, the pharmacy is operating illegally. This is a bright-line rule. Compounding is only legal during shortages.

Red flag 6: Marketing language that mimics pharmaceutical advertising. Phrases like "clinically proven," "FDA-quality," or "pharmaceutical-grade" are red flags. Compounded medications cannot make these claims. Pharmacies using this language are either confused about the regulatory framework or deliberately deceptive.

Red flag 7: No licensed provider involvement. Some websites sell "compounded semaglutide" without requiring a prescription or provider consultation. This is illegal. All compounded medications require a valid prescription from a licensed provider.

Red flag 8: Shipping compounded medications internationally. Compounded medications are only legal for patients within the state where the pharmacy is licensed (or states with reciprocal agreements). A pharmacy shipping compounded semaglutide to patients in 20+ states is likely violating state pharmacy laws.

If you see two or more of these red flags, do not use that pharmacy. The risk of contamination, incorrect potency, or legal problems outweighs any cost savings.

FAQ

What is a weight loss pharmacy? A weight loss pharmacy is a compounding facility that prepares custom formulations of GLP-1 medications like semaglutide and tirzepatide. These pharmacies operate under state and federal compounding regulations, creating patient-specific prescriptions during FDA shortage periods. They differ from retail pharmacies by manufacturing the medication rather than dispensing pre-made products.

Are compounded weight loss medications safe? Safety depends on the specific pharmacy's quality systems. Compounded medications from pharmacies that follow USP 797 standards, perform sterility testing on every batch, and source API from FDA-registered suppliers are generally safe. Compounded medications from pharmacies that cut corners on testing or use questionable API sources carry higher risk. The five vetting questions in this article help distinguish safe from risky pharmacies.

How much do compounded GLP-1 medications cost? Compounded semaglutide costs $200 to $400 per month through most telehealth platforms. Compounded tirzepatide costs $300 to $500 per month. Prices vary based on dose, pharmacy, and whether the platform includes provider visits and labs in the monthly fee. Brand-name equivalents cost $900 to $1,400 per month without insurance.

Is compounded semaglutide the same as Wegovy? No. Compounded semaglutide contains the same active ingredient (semaglutide) but is prepared by a compounding pharmacy rather than Novo Nordisk. The formulation, concentration, and delivery method may differ. Compounded semaglutide is not FDA-approved and has not undergone the same clinical trials as Wegovy. The two are similar but not identical or interchangeable.

Can I use my insurance to pay for compounded weight loss medications? Rarely. Most insurance plans do not cover compounded medications, especially for weight loss. Some plans cover compounded medications if the brand-name version is unavailable or if the patient has a documented allergy to an ingredient in the brand-name product. Check with your insurance, but expect to pay out of pocket.

How do I know if a weight loss pharmacy is legitimate? Verify the pharmacy has an active state license (check your state pharmacy board website), ask the five vetting questions (sterility testing, API sourcing, adverse event reporting, potency verification, batch failure rate), and confirm the pharmacy follows USP 797 sterile compounding standards. If the pharmacy cannot answer these questions or refuses to provide documentation, choose a different pharmacy.

What is USP 797 and why does it matter? USP 797 is the United States Pharmacopeia standard for sterile compounding. It specifies requirements for cleanroom design, environmental monitoring, sterility testing, and personnel training. All pharmacies compounding injectable medications (including semaglutide and tirzepatide) must follow USP 797. Pharmacies that do not follow USP 797 are operating illegally and producing unsafe products.

Can compounding pharmacies make GLP-1 medications when there is no shortage? No. Under FDA Section 503A, pharmacies can only compound copies of commercially available drugs during FDA-declared shortages. If FDA removes semaglutide and tirzepatide from the shortage list, compounding pharmacies must stop producing these medications within 60 days. As of April 2026, both remain on the shortage list.

What happens if my compounded medication is contaminated? Contact the pharmacy and your provider immediately. Stop using the medication. The pharmacy should investigate, test remaining product from the same batch, and report the contamination to FDA if confirmed. You should report the adverse event to FDA via MedWatch. Depending on the type of contamination, you may need medical evaluation (blood cultures for bacterial contamination, liver function tests for endotoxin exposure).

Do compounded GLP-1 medications work as well as brand-name versions? Clinical data is limited because compounded medications are not studied in large trials. Anecdotal evidence from providers suggests similar efficacy when the compounded product is properly formulated and stored. The main variables are potency accuracy (does the vial contain the labeled amount of drug) and patient adherence (compounded versions require manual injection, which some patients find harder than pre-filled pens).

Why are compounded medications so much cheaper than brand-name? Compounded medications avoid five cost layers: drug development cost recovery, marketing spend, device manufacturing (pre-filled pens), insurance middlemen (PBMs and wholesalers), and pharmaceutical profit margins. The API itself is inexpensive ($2-3 per dose). The price difference reflects business model differences, not quality differences when properly compounded.

Can I switch from brand-name to compounded or vice versa? Yes, but work with your provider to manage the transition. Compounded and brand-name products may have slightly different pharmacokinetics due to formulation differences. Some patients notice increased side effects or reduced efficacy when switching. The transition is usually smooth but requires monitoring. Do not switch on your own without provider guidance.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Molecular Metabolism. 2021.
4. United States Pharmacopeia. General Chapter 797: Pharmaceutical Compounding - Sterile Preparations. USP 43-NF 38. 2020.
5. United States Pharmacopeia. General Chapter 795: Pharmaceutical Compounding - Nonsterile Preparations. USP 43-NF 38. 2020.
6. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA Guidance. 2023.
7. Food and Drug Administration. Drug Shortages: Current and Resolved Drug Shortages and Discontinuations Reported to FDA. Updated monthly. 2026.
8. Pharmacy Compounding Accreditation Board. PCAB Accreditation Standards for Compounding Pharmacies. 2024.
9. Allen LV et al. The Art, Science, and Technology of Pharmaceutical Compounding. 5th edition. American Pharmacists Association. 2020.
10. Outterson K et al. Will Shorter Antibiotic Courses Improve Patient Outcomes? Clinical Infectious Diseases. 2019.
11. Centers for Disease Control and Prevention. Multistate Outbreak of Fungal Meningitis and Other Infections: Case Count. CDC Report. 2013.
12. Kantar Media. Pharmaceutical Advertising Spending in the United States. Annual Report. 2024.
13. American Society of Health-System Pharmacists. ASHP Guidelines on Compounding Sterile Preparations. American Journal of Health-System Pharmacy. 2023.
14. National Association of Boards of Pharmacy. Survey of Pharmacy Law: Compounding Regulations by State. NABP Report. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Saxenda, and Victoza are registered trademarks of Novo Nordisk. Zepbound, Mounjaro, and Trulicity are registered trademarks of Eli Lilly and Company. Contrave is a registered trademark of Currax Pharmaceuticals. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.